Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
Zola Matuvanga T, Larivière Y, Lemey G, De Bie J, Milolo S, Meta R, Esanga E, Vermeiren PP, Thys S, Van Geertruyden JP, Van Damme P, Maketa V, Matangila J, Mitashi P, Muhindo-Mavoko H. Zola Matuvanga T, et al. Vaccine. 2022 May 31;40(25):3470-3480. doi: 10.1016/j.vaccine.2022.04.094. Epub 2022 May 9. Vaccine. 2022. PMID: 35550847 Free article.
Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods Study.
Zola Matuvanga T, Johnson G, Larivière Y, Esanga Longomo E, Matangila J, Maketa V, Lapika B, Mitashi P, Mc Kenna P, De Bie J, Van Geertruyden JP, Van Damme P, Muhindo Mavoko H. Zola Matuvanga T, et al. J Med Internet Res. 2021 Aug 9;23(8):e28573. doi: 10.2196/28573. J Med Internet Res. 2021. PMID: 34378545 Free PMC article. Clinical Trial.
Longitudinal assessment of an Ebola vaccine trial understanding among healthcare providers in the Democratic Republic of the Congo.
Zola Matuvanga T, Larivière Y, Lemey G, Isekah Osang'ir B, Mariën J, Milolo S, Meta R, Matangila J, Maketa V, Mitashi P, Van Geertruyden JP, Muhindo-Mavoko H, Van Damme P. Zola Matuvanga T, et al. Vaccine. 2024 Jan 25;42(3):481-488. doi: 10.1016/j.vaccine.2023.12.076. Epub 2023 Dec 31. Vaccine. 2024. PMID: 38163747 Free article.
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
Larivière Y, Garcia-Fogeda I, Zola Matuvanga T, Isekah Osang'ir B, Milolo S, Meta R, Kimbulu P, Robinson C, Katwere M, McLean C, Hens N, Matangila J, Maketa V, Mitashi P, Muhindo-Mavoko H, Van Geertruyden JP, Van Damme P. Larivière Y, et al. Among authors: zola matuvanga t. J Infect Dis. 2024 Apr 12;229(4):1068-1076. doi: 10.1093/infdis/jiad350. J Infect Dis. 2024. PMID: 37673423 Free PMC article.
Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo.
Zola Matuvanga T, Mariën J, Larivière Y, Osang'ir BI, Milolo S, Meta R, Esanga E, Maketa V, Matangila J, Mitashi P, Ahuka Mundeke S, Muhindo-Mavoko H, Muyembe Tamfum JJ, Van Damme P, Van Geertruyden JP. Zola Matuvanga T, et al. PLoS One. 2023 Sep 1;18(9):e0286479. doi: 10.1371/journal.pone.0286479. eCollection 2023. PLoS One. 2023. PMID: 37656725 Free PMC article.